Led · Seed · Mar 2023

Caramel offers a simple digital checkout platform that simplifies private party and independent dealer car sales by handling authentication, payments, title transfers and DMV work. The platform verifies buyers and sellers with photo ID and selfies, authenticates vehicles, transfers funds securely, automates digital paperwork, and offers financing, insurance and transportation options from national partners. Dozens of independent dealers already use Caramel as a digital retail solution, and the product is available in the App Store, Google Play and at drivecaramel.com. Founded and led by co-CEOs Craig Nehamen and Ed Brojerdi, the team draws on experience in auto finance, operations, marketing and product. Caramel says it launched the checkout platform to make private-party transactions easier and more secure for buyers and sellers. Financially, the company completed a $12 million seed funding round announced alongside the product launch.

Led · Series A · Mar 2023

Glider AI provides a skill intelligence platform for enterprise hiring and staffing, offering screening, assessments, coding and video interviews, and upskilling software. Its solution includes over 250,000 questions, 35+ interactive question types and 500+ competencies across technical and non-technical roles, enabling hands-on tasks that replicate real-world scenarios. The platform identifies employee skill gaps to support reskilling and upskilling initiatives and is commonly used for deep skill evaluation. Glider AI serves global enterprises and leading staffing firms, including customers such as Intuit, PwC, Applied Materials, Carmax and FINRA. The company intends to use new funding to expand in contingent programs and permanent hiring, further develop proprietary technology, and grow its global team.

Participated · Series A · Nov 2021

mimik Technology offers a hybrid edge cloud computing application development platform that enables edge-native applications across device and cloud ecosystems. The platform supports iOS, Android, Windows, macOS, Linux, QNX, Raspbian, OpenWRT and IoT FreeRTOS sensors, and aims to connect siloed applications from the edge with minimal reliance on middlemen. mimik positions its technology to help enterprises save millions in legacy backend integration and reduce ongoing operational costs through an edge-in approach. The company emphasizes interoperability, data privacy, security and avoiding lock-in to proprietary stacks. In November 2021 mimik announced a $14.3M Series A to support growth. The funds will be used to expand global go-to-market operations including sales, solutions delivery, developer outreach, technical training and partnership development.

Participated · Series A · Oct 2021

Vfunction provides a platform that automates breaking monolithic Java applications into microservices to expedite cloud-native modernization. The company split its offering into two products: the Vfunction management platform for estate assessment and the Vfunction application transformation engine for code transformation. Customers deploy a JVM agent that sends data for human-architect-reviewed recommendations; the platform uses supervised learning, graph theory, and clustering to identify redundancies and untether dependencies. Typical customers are large enterprises in financial services, automotive, telco, media, and government, and it has attracted major clients such as Intesa Sanpaolo. The Palo Alto–based company exited stealth in February with $12M in seed funding and has now raised additional capital. Vfunction plans to invest the new funding in global growth beyond North America and Europe. Vfunction provides a platform that automates decomposition of legacy monolithic applications into cloud-native microservices, deploying locally with a JVM agent that sends data to a central server where architects design target services. The platform generates service specification files which an automation engine uses to copy relevant code artifacts to create new services. Vfunction leverages supervised learning, graph theory, and clustering algorithms to identify dead code and code anomalies, while keeping the human architect in control to modify or override recommendations. The company says its automation can make decomposition up to 15x faster and achieve 80–95% automation depending on the application and target architecture. During stealth it secured six- and seven-figure deals with leading banks and disclosed Italy's Intesa Sanpaolo as a paying customer. At launch Vfunction is focused on Java (JVM) with plans to support additional languages and platforms over time; the company was founded in 2017.

Participated · Series C · Dec 2020

Biosight is a private Phase 2 clinical‑stage biotechnology company developing therapeutics for hematological malignancies and disorders. Its lead asset, BST‑236 (aspacytarabine), is a proprietary anti‑metabolite composed of cytarabine covalently bound to asparagine and acts as a pro‑drug designed to enable high‑dose therapy with lower systemic exposure and reduced toxicity. BST‑236 has received FDA Fast Track and Orphan Drug designations and is being investigated as a single‑agent first‑line treatment for AML in a multi‑center Phase 2b trial in the U.S. and Israel. Biosight plans to expand BST‑236 into two additional Phase 2 trials — one in Europe and another in the U.S. — to evaluate relapsed/refractory MDS and AML, including a collaboration with the European cooperative group GFM. The company completed a deferred close of its Series C, bringing total proceeds to $46M to advance these clinical programs. Management states the funds will support additional clinical launches and continued enrollment in the ongoing Phase 2b study, with updated data reported at the 2020 ASH Annual Meeting. BioSight develops innovative chemotherapy pro-drugs designed to reduce toxicity, with a lead candidate called Astarabine. Astarabine is a compound of the chemotherapy drug cytarabine (Ara-C) and the amino acid asparagine intended for the treatment of AML. The company is completing a Phase I/IIa clinical trial of Astarabine as monotherapy for AML and ALL at Rambam Hospital under the supervision of Dr. Tsila Zuckerman. BioSight plans to advance Astarabine into a multi-center Phase IIb clinical trial using recently raised funds. The company is led by Co-Founder and Chief Scientist Stela Gengrinovitch, PhD, and CEO Ruth Ben Yakar, PhD. BioSight is based in Karmiel, Israel.